Randomised Study for Double-blind, Placebo-controlled Evaluation of a Single Intravenous Infusion of BI 765845 and Partially-blinded Evaluation of a Single Bolus Administration of BI 765845 on Top of Standard of Care in Patients With Acute Myocardial Infarction
Latest Information Update: 11 Jul 2025
At a glance
- Drugs BI-765845 (Primary)
- Indications Myocardial infarction
- Focus Therapeutic Use
- Acronyms IRI-EXPLORE
- Sponsors Boehringer Ingelheim
Most Recent Events
- 24 Jan 2025 Protocol has been amended to include new arms, changed from 5 to 7, type 2 for low and high doses group has been added.
- 06 Dec 2023 Status changed from not yet recruiting to recruiting.
- 24 Nov 2023 New trial record